Chompions! A Treatment Study for Childhood Avoidant/Restrictive Food Intake Disorder (ARFID) (NCT05105308) | Clinical Trial Compass
CompletedNot Applicable
Chompions! A Treatment Study for Childhood Avoidant/Restrictive Food Intake Disorder (ARFID)
United States203 participantsStarted 2022-02-10
Plain-language summary
Avoidant Restrictive Food Intake Disorder (ARFID) is a disorder that affects toddlers, children, adolescents, and adults. Individuals with ARFID are not able to consume an adequate amount or variety of food to a degree that it affects their mental and/or physical health. ARFID often begins in early childhood so it is important to treat children in early in life as possible to prevent any negative consequences of poor nutrition. There are currently no treatments for young children with ARFID. The investigators have developed two different study programs and the purpose of this study is to test them out and see if they help children with ARFID and to learn more about how these study programs work.
Who can participate
Age range
60 Months – 119 Months
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Child is between 60 and 119 months (5 years and up to 9 years, 11 months)
* English Speaking
* Consent given by parent and assent by child
And any one or more of the following:
* Score of 29 or above on the Child Food Neophobia Scale
* Underweight
* Current diagnosis of ARFID
* Dependent on nutritional supplements to achieve sufficient calories for optimal growth
* Avoiding activities due to eating rated at least almost always
Exclusion Criteria:
* Child is known to have a severe intellectual disability based on medical chart review
* Meets diagnostic criteria for anorexia nervosa or bulimia nervosa
* Is currently enrolled in a treatment study or receiving active treatment for ARFID
* Taking medications known to affect appetite
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in the number of clinically severe symptoms of Avoidant Restrictive Food Intake Disorder (ARFID) as measured by the PARDI (Pica, ARFID, and Rumination Diagnostic Interview)
Timeframe: Baseline, Post-Treatment (up to 30 weeks), 3-Months Post-Treatment